Results 221 to 230 of about 56,774 (264)
Some of the next articles are maybe not open access.
Therapeutic inertia in relapsing-remitting multiple sclerosis
Multiple Sclerosis and Related Disorders, 2021Therapeutic inertia (TI) is defined as a failure to initiate or intensify treatments despite evidence of disease activity. Its prevalence and determining factors in Relapsing-Remitting Multiple Sclerosis (RRMS) patients in Portugal are not known. The main objective of this work was to ascertain the prevalence of TI in RRMS and its determining factors ...
Rita, Rodrigues +12 more
openaire +2 more sources
Fingolimod for relapsing-remitting multiple sclerosis
Cochrane Database of Systematic Reviews, 2016Fingolimod was approved in 2010 for the treatment of patients with the relapsing-remitting (RR) form of multiple sclerosis (MS). It was designed to reduce the frequency of exacerbations and to delay disability worsening. Issues on its safety and efficacy, mainly as compared to other disease modifying drugs (DMDs), have been raised.To assess the safety ...
Loredana, La Mantia +5 more
openaire +2 more sources
[Relapsing-Remitting Multiple Sclerosis].
Brain and nerve = Shinkei kenkyu no shinpo, 2021Multiple sclerosis (MS) is an immune-mediated inflammatory demyelinating disease of the central nervous system. There are neither diagnostic tests nor markers for MS. Other causes must be excluded thoroughly before an MS diagnosis is considered definitive. The relapsing-remitting type is a major clinical course in MS. Most disease-modifying drugs (DMDs)
Masaaki, Niino, Yusei, Miyazaki
openaire +1 more source
Cyclophosphamide in relapsing remitting multiple sclerosis
The Italian Journal of Neurological Sciences, 19907 patients with relapsing-remitting multiple sclerosis (MS) were subjected to an intensive course of intravenous (I.V.) cyclophosphamide (CY) therapy. All patients received induction therapy with 11 daily doses of 300 mg/m2 and then a single dose every six months for three years.
F, D'Andrea +3 more
openaire +4 more sources
Daclizumab for relapsing remitting multiple sclerosis
Cochrane Database of Systematic Reviews, 2012The anti-CD25 treatment of daclizumab appears to be effective in patients with relapsing remitting multiple sclerosis (RRMS) as regards clinical and MRI outcomes. Moreover, there are no severe safety concerns arising from clinical testing so far.To assess the efficacy and safety of daclizumab for the clinical progression of patients with relapsing ...
Jia, Liu +3 more
openaire +3 more sources
Rituximab for relapsing-remitting multiple sclerosis
Cochrane Database of Systematic Reviews, 2013This is an update of the Cochrane review "Rituximab for relapsing-remitting multiple sclerosis" (first published in The Cochrane Library 2011, Issue 12).More than 80% of individuals with multiple sclerosis (MS) experience a relapsing-remitting disease course.
Dian, He +5 more
openaire +2 more sources
Executive functions in relapsing-remitting multiple sclerosis
Applied Neuropsychology: Adult, 2023Some studies suggest that patients with relapsing-remitting multiple sclerosis have problems in the functioning of working memory, and more specifically in executive functions, but the available results are still inconsistent. The aim of the present study was to examine executive functioning in multiple sclerosis using classical and representative ...
M. Rosa Elosúa, Noelia Villadangos
openaire +2 more sources
Ibudilast in relapsing-remitting multiple sclerosis
Neurology, 2010Ibudilast is a phosphodiesterase inhibitor influencing inflammation and neurodegeneration in multiple sclerosis (MS). This study evaluated the safety, tolerability, and effects on MRI parameters of 2 different doses of ibudilast in relapsing forms of MS.In this multicenter, double-blind, phase 2 trial, patients with relapsing MS and gadolinium ...
Barkhof, F. +5 more
openaire +3 more sources
Rituximab for relapsing-remitting multiple sclerosis
2011More than 80% of individuals with multiple sclerosis (MS) experience a relapsing-remitting disease course. Approximately ten years after disease onset, an estimated 50% of individuals with relapsing-remitting MS (RR-MS) convert to secondary progressive MS. Quality of life is considerably impaired in early RR-MS.
Dian, He +3 more
openaire +2 more sources
Daclizumab for relapsing remitting multiple sclerosis
2009The anti-CD25 treatment of daclizumab appears to be effective in patients with relapsing remitting multiple sclerosis (RRMS) as regards clinical and MRI outcomes. Moreover, there are no severe safety concerns arising from clinical testing so far.To assess the efficacy and safety of daclizumab for patients with relapsing remitting multiple sclerosis.We ...
Jia, Liu +4 more
openaire +2 more sources